Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Invivoscribe Announces a Regional “Center of Excellence” Reference Laboratory in Beirut to Offer Specialized Gene Panels

Invivoscribe Technologies Inc., a global precision diagnostics company in oncology and personalized molecular medicine, announces a partnership with the American University of Beirut Medical Center (AUBMC) in Lebanon to create a new Center of Excellence. This facility will serve as an international service laboratory in the Middle East, testing for all hematologic diseases, including leukemia and lymphoma. This partnership will enable the American University of Beirut Medical Center to provide pharmaceutical and clinical partners in the Middle East the same high quality, reliable, standardized tests and bioinformatics tools provided by Invivoscribe’sLabPMM clinical laboratories in the U.S.A., Japan and Germany. The establishment of this center also facilitates quicker turnaround times, which are important for clinical trial enrollment and tracking of patients during the course of treatment.

The Center of Excellence at the CAP-accredited Molecular Diagnostics Laboratory of the American University of Beirut Medical Center will expand the range of diagnostic services available in the Middle East, bringing a comprehensive array of new tests designed and manufactured in an ISO 13485 accredited facility. Most importantly, through this partnership, Invivoscribe’s specialized next-generation sequencing (NGS) gene panel tests including MyAML®, MyHeme®, and MyMRD® will become available in the Middle East. These tests identify and track primary driver mutations and their subclonal architectures, as well as the emergence of new driver mutations in patients with hematologic diseases. Other available tests include the comprehensive menu of IdentiClone® and LymphoTrack® Dx Assays for clonality, minimal residual disease (MRD) and somatic hypermutation testing. This Center of Excellence is the first of many that will facilitate international standardization of testing services, allowing medical centers around the world unprecedented access to Invivoscribe’s proprietary assays and bioinformatics.

About Invivoscribe

Invivoscribe Technologies Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, standardized reagents, tests, and bioinformatics tools to advance the fields of personalized molecular diagnostics and personalized molecular medicine. Invivoscribe’s PCR and NGS-based tests, reagents and bioinformatics tools are currently being used in more than 700 clinical and research laboratories in more than 160 countries.  Invivoscribe currently has clinical laboratories located in North America, Europe and Asia, which provide international access to harmonized CLIA, CAP, and ISO 15189 accredited clinical testing and contract research organization (CRO) services. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies developing and commercializing companion diagnostics. As an international leader, Invivoscribe has long embraced the value of quality systems and develops all IVD products, including bioinformatics software, in compliance with ISO 13485 design controls, making them eligible to be submitted to worldwide regulatory authorities for registration.

For additional information please visit www.invivoscribe.com.